Iksuda Therapeutics
PrivateLast Round
Strategic
Jun 15, 2025
Est. Valuation
$93.98M
Total Funding Raised
$68.74M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Iksuda Therapeutics operates in Healthcare & Life Sciences and is based in Newcastle upon Tyne. Its latest recorded funding round was a Strategic round in November 2024.
Iksuda Therapeutics is a biotechnology company that develops next-generation Antibody-Drug Conjugates (ADCs) for the treatment of difficult-to-treat haematological and solid tumours.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Iksuda Therapeutics Comparables
Compare Iksuda Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MediLink Therapeutics | 83% | |
| Sutro Biopharma Inc | 82% | |
| Seekyo | 81% |
For institutional investors. Book with your work email.
Iksuda Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Jun 15, 2025 | ||||
| Corporate Funding | Mar 21, 2025 | ||||
| Strategic | Nov 15, 2024 | ||||
| Series A | Jun 7, 2021 | ||||
| Grant | Jun 6, 2017 | ||||
Grant | Jul 27, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Iksuda Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LigaChem Biosciences | Corporate Funding, Strategic |
| IP Group | Series A, Seed |
| North East Access to Finance | Seed |
| Premier Partners | Series A |
| Mirae Asset Securities | Series A |
| Mirae Asset Capital | Series A |
| Centre for Process Innovation | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 40% MoM, reaching 4K.
- Jul 25, 2026
Monthly visitors grew 41% MoM, reaching 2.8K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 5, 2026
Iksuda attends the 68th American Society of Hematology (ASH) Annual Meeting and presents preliminary Phase 1 IKS03 data in Louisiana on Dec 12th-15th '26.
- attends_eventNov 2, 2026
Iksuda attends the San Antonio Breast Cancer Symposium in Texas on Dec 8th-11th '26 to present preliminary Phase 1 data for its HER2-directed ADC, IKS014.
For institutional investors. Book with your work email.
Iksuda Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Iksuda Therapeutics's valuation, stock price, and market status.
Is Iksuda Therapeutics a public or private company?
Iksuda Therapeutics is a private company.
What is the current stock price of Iksuda Therapeutics?
Iksuda Therapeutics is a private company, so its shares have no public market price. Caplight tracks Iksuda Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Iksuda Therapeutics worth (valuation)?
Iksuda Therapeutics's valuation is estimated at $94.0M based on funding round data.
Can I buy Iksuda Therapeutics stock?
Iksuda Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Iksuda Therapeutics's last funding round?
Iksuda Therapeutics's most recent funding round was Strategic on June 15, 2025.
Who are the main investors in Iksuda Therapeutics?
Key investors in Iksuda Therapeutics include LigaChem Biosciences, IP Group, Innovate UK, Mirae Asset Capital, Mirae Asset Capital.
Will Iksuda Therapeutics IPO soon?
No public IPO plans have been announced for Iksuda Therapeutics.
How can I track Iksuda Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Iksuda Therapeutics's shares on secondary markets.